MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced completion of enrollment in the BIOADAPTOR randomized controlled ...

MILPITAS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced new landmark clinical results for its ...

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the first patient has been treated in the BIOADAPTOR randomized ...

Washington D.C. – October 28, 2024 – Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced late-breaking data demonstrating significant benefit of the ...

Drug Eluting Stents (DES) are the mainstay of coronary artery disease treatment. Although DES design iterations have reduced MACE in the first year after PCI, beyond 1-year, a persistent 2-3% ...

Consumers now broadcast their opinions instantly to thousands, or even millions, of people from wherever they are. Social Dynamx quickly identifies relevant conversations and intelligently routes them ...

Lithium Technologies, a developer of customer community platforms, has acquired enterprise social customer care solution Social Dynamx. The company also announced the general release of the product ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Lithium Technologies has issued $5.6 million in shares to power its ...

Lithium has bought up social CRM provider Social Dynamx and turned it into Lithium Social Web, a social customer care service capable of responding to the deluge of social commentary now found in the ...

Social CRM company Lithium Technologies has acquired fellow customer care application Social Dynamx. The financial terms of the deal were not disclosed. Social Dynamx’s platform is designed for large ...

DynamX® bioadaptor is the first interventional technology to demonstrate significant benefit with a reduction in long term adverse events in two consecutive randomized controlled trials MILPITAS, ...